An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.

Area of Science:

• Medical Research
• Pharmacology
• Genetics

Background:

• Significant advancements in Cystic Fibrosis Transmembrane Regulator (CFTR) modulator drugs have occurred over the last decade.
• Initial treatments focused on potentiators like ivacaftor for common gating mutations.
• Development of corrector drugs led to highly effective combination therapies, expanding treatment accessibility.

Purpose of the Study:

• To review clinical trial and real-world data on the impact of highly effective CFTR modulators.
• To discuss challenges in demonstrating drug efficacy in younger populations and in a shrinking pool of modulator-naïve individuals.
• To explore drug-drug interactions, treatment burden, and emerging therapies for non-modulatable genes and gene therapy.

Main Methods:

• Review of clinical trial evidence.
• Analysis of real-world observational and registry data.
• Summary of ongoing and early-stage drug development.

Main Results:

• Highly effective modulators (e.g., elexacaftor/tezacaftor/ivacaftor) are available to over 85% of cystic fibrosis patients aged 12+.
• These modulators demonstrate significant impact on both pulmonary and extra-pulmonary manifestations of cystic fibrosis.
• Challenges exist in assessing efficacy in early life and for a diminishing modulator-naïve population.

Conclusions:

• CFTR modulator therapy has transformed cystic fibrosis care, improving outcomes across various disease aspects.
• Future research needs to address challenges in pediatric populations, drug interactions, treatment burden, and health inequities.
• Promising early-stage developments exist for non-genetically eligible patients, including gene therapy approaches.